SCYNEXIS Inkomsten in het verleden

Verleden criteriumcontroles 0/6

SCYNEXIS is de winst gegroeid met een gemiddeld jaarlijks percentage van 28%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 1.2%. De inkomsten zijn gegroeid met een gemiddelde van 62.9% per jaar.

Belangrijke informatie

28.0%

Groei van de winst

57.0%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	6.0%
Inkomstengroei	62.9%
Rendement op eigen vermogen	-62.3%
Nettomarge	-425.4%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 08

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

Jun 19

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

May 12

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Sep 26

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Aug 17

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Aug 26

SCYNEXIS Q2 2022 Earnings Preview

Aug 12

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Aug 01

SCYNEXIS gains after favorable data for antifungal agent in new indication

Jul 19

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Apr 07

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

Mar 07

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Feb 13

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

Dec 03

Scynexis: Leading The Yeast Infection Treatment Industry

Jul 27

Scynexis' Brexafemme qualifies for 10 years of exclusivity for vaginal yeast infections

Jun 09

FDA approves SCYNEXIS' BREXAFEMME vaginal yeast infections treatment

Jun 02

Opbrengsten en kosten

Hoe SCYNEXIS geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:SCYX Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	9	-36	14	33
30 Jun 24	10	-35	15	31
31 Mar 24	140	101	20	31
31 Dec 23	140	67	21	31
30 Sep 23	136	72	32	28
30 Jun 23	136	44	45	28
31 Mar 23	6	-91	53	28
31 Dec 22	5	-63	63	27
30 Sep 22	4	-78	62	27
30 Jun 22	3	-49	61	25
31 Mar 22	2	-34	58	23
31 Dec 21	13	-33	50	24
30 Sep 21	13	-46	40	26
30 Jun 21	12	-45	28	30
31 Mar 21	12	-53	19	34
31 Dec 20	0	-55	15	37
30 Sep 20	0	-27	13	37
30 Jun 20	0	-36	12	39
31 Mar 20	0	-38	11	39
31 Dec 19	0	-54	11	38
30 Sep 19	0	-37	10	34
30 Jun 19	0	-29	10	29
31 Mar 19	0	-31	9	26
31 Dec 18	0	-12	9	22
30 Sep 18	0	-22	8	20
30 Jun 18	0	-31	8	21
31 Mar 18	0	-24	8	20
31 Dec 17	0	-25	8	18
30 Sep 17	0	-21	8	17
30 Jun 17	0	-24	8	17
31 Mar 17	0	-28	7	19
31 Dec 16	0	-30	8	20
30 Sep 16	0	-35	9	22
30 Jun 16	0	-31	11	21
31 Mar 16	0	-30	12	17
31 Dec 15	0	-28	12	16
30 Sep 15	1	-23	12	13
30 Jun 15	1	-19	10	12
31 Mar 15	1	-11	9	11
31 Dec 14	1	-7	8	8
30 Sep 14	4	-42	7	7
30 Jun 14	8	-43	6	5
31 Mar 14	12	-47	4	5
31 Dec 13	17	-47	4	4

Kwaliteitswinsten: SCYX is momenteel verliesgevend.

Groeiende winstmarge: SCYX is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: SCYX is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 28% per jaar verminderd.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van SCYX over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: SCYX is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( 54.6% ).

Rendement op eigen vermogen

Hoge ROE: SCYX heeft een negatief Return on Equity ( -62.26% ), omdat het momenteel verliesgevend is.

SCYNEXIS Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

SCYNEXIS, Inc. to Report Q3, 2024 Results on Oct 18, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. to Report Q3, 2024 Results on Oct 18, 2024

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

SCYNEXIS, Inc., Annual General Meeting, Jun 19, 2024

Consensus estimates of losses per share improve by 12%

SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases

SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

Consensus revenue estimates fall by 59%

Scynexis: Update Following Restructuring Of GSK Deal

Full year 2023 earnings: EPS and revenues miss analyst expectations

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

Bronstein, Gewirtz & Grossman LLC Announces SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Price target decreased by 12% to US$7.13

Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

SCYNEXIS, Inc. Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology

SCYNEXIS, Inc. Issues A Voluntary Nationwide Recall of BREXAFEMME® (Ibrexafungerp Tablets) Due to Potential for Cross Contamination with A Non-Antibacterial ß-Lactam Drug Substance

Price target decreased by 9.6% to US$10.30

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 7.5% to US$11.40

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date moved forward to 2023

Forecast to breakeven in 2025

Scynexis AnnouncesFDA Approval of Second Indication for Brexafemme® (Ibrexafungerp Tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

Consensus revenue estimates fall by 35%

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$15.00

SCYNEXIS, Inc. Announces Positive Results from Pooled Analysis of Two Phase 3 Studies (VANISH-303 and VANISH-306) in the Journal of Women’s Health

SCYNEXIS, Inc. to Report Q3, 2022 Results on Nov 09, 2022

SCYNEXIS, Inc. Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022

SCYNEXIS, Inc. Announces CEO Changes

SCYNEXIS, Inc. Presents Positive Interim Data of ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$18.17

SCYNEXIS Q2 2022 Earnings Preview

SCYNEXIS, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting

SCYNEXIS, Inc. Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Scynexis Presents Positive Data from Phase 3 Candle Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the Issvd Xxvi World Congress and International Vulvovaginal Disease Update

SCYNEXIS gains after favorable data for antifungal agent in new indication

Scynexis Announces Initiation of New Phase 3B Study (Vanquish) to Evaluate Oral Ibrexafungerp as A Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole

SCYNEXIS, Inc. Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections

Consensus forecasts updated

Price target decreased to US$21.25

SCYNEXIS, Inc., Annual General Meeting, Jun 16, 2022

SCYNEXIS, Inc. Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

SCYNEXIS, Inc. to Report Q1, 2022 Results on May 12, 2022

No longer forecast to breakeven

Insufficient new directors

SCYNEXIS, Inc. has completed a Follow-on Equity Offering in the amount of $44.988333 million.

SCYNEXIS, Inc. Announces Positive Interim Data from its Ongoing Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Consensus revenue estimates fall by 30%